Abstract
The genes erm(B), mef(A), and both erm(B) and mef(A) were identified in 42.6, 10.1, and 47.3%, respectively, of the erythromycin-resistant Streptococcus pneumoniae isolates. Of the strains, 3.8% were nonsusceptible to levofloxacin and had 1 to 6 amino acid changes in the quinolone resistance-determining region, including a new mutation, Asn94Ser, in the product of parC. Levofloxacin with reserpine was highly specific for efflux screening.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Community-Acquired Infections / drug therapy
-
Community-Acquired Infections / epidemiology*
-
Community-Acquired Infections / microbiology
-
DNA, Bacterial
-
Drug Resistance, Bacterial / genetics*
-
Erythromycin / pharmacology
-
Fluoroquinolones / pharmacology
-
Genes, Bacterial
-
Hospitals
-
Humans
-
Korea / epidemiology
-
Levofloxacin
-
Macrolides / pharmacology
-
Microbial Sensitivity Tests
-
Molecular Epidemiology / methods*
-
Mutation
-
Ofloxacin / pharmacology
-
Pneumococcal Infections / epidemiology
-
Pneumococcal Infections / microbiology
-
Polymerase Chain Reaction
-
Prevalence
-
Reserpine / pharmacology
-
Respiratory Tract Infections / epidemiology
-
Respiratory Tract Infections / microbiology
-
Retrospective Studies
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / genetics
-
Streptococcus pneumoniae / isolation & purification
Substances
-
Anti-Bacterial Agents
-
DNA, Bacterial
-
Fluoroquinolones
-
Macrolides
-
Erythromycin
-
Levofloxacin
-
Reserpine
-
Ofloxacin